1. Home
  2. CAPR vs GILT Comparison

CAPR vs GILT Comparison

Compare CAPR & GILT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

N/A

Current Price

$30.60

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Logo Gilat Satellite Networks Ltd.

GILT

Gilat Satellite Networks Ltd.

N/A

Current Price

$17.50

Market Cap

1.1B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
CAPR
GILT
Founded
2005
1987
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Radio And Television Broadcasting And Communications Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
2011
1997

Fundamental Metrics

Financial Performance
Metric
CAPR
GILT
Price
$30.60
$17.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
1
Target Price
$41.38
$20.00
AVG Volume (30 Days)
921.3K
1.0M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$22,270,465.00
N/A
Revenue This Year
N/A
$15.06
Revenue Next Year
$17,308.50
$11.72
P/E Ratio
N/A
$42.82
Revenue Growth
N/A
N/A
52 Week Low
$4.30
$5.30
52 Week High
$40.37
$20.38

Technical Indicators

Market Signals
Indicator
CAPR
GILT
Relative Strength Index (RSI) 66.95 56.16
Support Level $22.09 $13.11
Resistance Level $40.37 $20.38
Average True Range (ATR) 1.84 0.86
MACD 0.17 0.19
Stochastic Oscillator 92.68 86.62

Price Performance

Historical Comparison
CAPR
GILT

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About GILT Gilat Satellite Networks Ltd.

Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company's solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense, and public safety.

Share on Social Networks: